• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.

作者信息

Behr Paulo Eduardo Ballvé, Moriguchi Emilio Hideyuki, Castro Iran, Bodanese Luiz Carlos, Dutra Oscar Pereira, Leães Paulo Ernesto, Pimentel Filho Pedro

机构信息

Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS - Brazil.

Faculdade de Medicina - Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brazil.

出版信息

Arq Bras Cardiol. 2018 Jul;111(1):104-108. doi: 10.5935/abc.20180133.

DOI:10.5935/abc.20180133
PMID:30110052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6078356/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9204/6078356/c63992b16d10/abc-111-01-0104-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9204/6078356/c63992b16d10/abc-111-01-0104-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9204/6078356/c63992b16d10/abc-111-01-0104-g01.jpg

相似文献

1
Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂在心血管风险高和极高的患者中的应用指征
Arq Bras Cardiol. 2018 Jul;111(1):104-108. doi: 10.5935/abc.20180133.
2
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.基于FOURIER试验结果的PCSK9抑制剂最新成本效益分析
JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924.
3
Do PCSK9 inhibitors reduce cardiovascular events?前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂能否降低心血管事件的发生？
Can Fam Physician. 2018 Sep;64(9):669.
4
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
5
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.用于治疗高胆固醇水平的前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂：有效性和价值。
JAMA Intern Med. 2016 Jan;176(1):107-8. doi: 10.1001/jamainternmed.2015.7248.
6
[PCSK9 inhibitors reduces LDL cholesterol by 60 percent].前蛋白转化酶枯草溶菌素9抑制剂可使低密度脂蛋白胆固醇降低60%。
Lakartidningen. 2017 Mar 30;114:ELPY.
7
Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.PCSK9 抑制剂在预防心血管疾病方面的经济学评价。
Curr Cardiol Rep. 2018 May 19;20(7):51. doi: 10.1007/s11886-018-0993-8.
8
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.1090例高胆固醇血症患者尽管接受了最大耐受的低密度脂蛋白胆固醇降低治疗，但低密度脂蛋白胆固醇仍≥70mg/dL，他们被转诊至一家地区胆固醇治疗中心，符合alirocumab或evolocumab治疗的条件。
Vasc Health Risk Manag. 2017 Jul 6;13:247-253. doi: 10.2147/VHRM.S133690. eCollection 2017.
9
Proprotein Convertase Subtilisin Kexin 9 Inhibitors.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂
Cardiol Clin. 2018 May;36(2):241-256. doi: 10.1016/j.ccl.2017.12.006.
10
PCSK9 inhibitors: smooth sailing or a little turbulence ahead?
Lancet Diabetes Endocrinol. 2017 Jul;5(7):490-492. doi: 10.1016/S2213-8587(17)30150-X. Epub 2017 May 5.

引用本文的文献

1
Impact of manufacturer-initiated list price reduction on patient out-of-pocket costs for inhibitors.制造商发起的目录降价对抑制剂患者自付费用的影响。
J Manag Care Spec Pharm. 2024 Oct;30(10):1078-1086. doi: 10.18553/jmcp.2024.30.10.1078.
2
The Challenge of Incorporating High-Cost Technologies: An Analysis of PCSK9 Inhibitors.纳入高成本技术的挑战：PCSK9抑制剂分析
Arq Bras Cardiol. 2021 Nov;117(5):997-998. doi: 10.36660/abc.20210840.
3
The number needed to benefit: estimating the value of predictive analytics in healthcare.

本文引用的文献

1
Cognitive Function in a Randomized Trial of Evolocumab.依洛尤单抗的随机临床试验中的认知功能。
N Engl J Med. 2017 Aug 17;377(7):633-643. doi: 10.1056/NEJMoa1701131.
2
[Not Available].[无可用内容]。
Arq Bras Cardiol. 2017 Jul;109(2 Supl 1):1-76. doi: 10.5935/abc.20170121.
3
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.低密度脂蛋白导致动脉粥样硬化性心血管疾病。1. 来自遗传、流行病学和临床研究的证据。欧洲动脉粥样硬化学会共识小组的共识声明。
需要治疗的人数：评估预测分析在医疗保健中的价值。
J Am Med Inform Assoc. 2019 Dec 1;26(12):1655-1659. doi: 10.1093/jamia/ocz088.
Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.
4
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.Bococizumab 在高危患者中的心血管疗效和安全性。
N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.
5
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
6
Determining When to Add Nonstatin Therapy: A Quantitative Approach.确定何时加用非他汀类药物治疗：一种定量方法。
J Am Coll Cardiol. 2016 Dec 6;68(22):2412-2421. doi: 10.1016/j.jacc.2016.09.928.
7
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.对重度高胆固醇血症患者进行家族性高胆固醇血症基因测序的诊断率及临床应用价值
J Am Coll Cardiol. 2016 Jun 7;67(22):2578-89. doi: 10.1016/j.jacc.2016.03.520. Epub 2016 Apr 3.
8
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.2016年美国心脏病学会临床专家共识文件特别工作组报告：非他汀类疗法在降低低密度脂蛋白胆固醇以管理动脉粥样硬化性心血管疾病风险中的作用专家共识决策路径
J Am Coll Cardiol. 2016 Jul 5;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. Epub 2016 Apr 1.
9
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.高强度他汀类药物治疗后低密度脂蛋白胆固醇的降低百分比：对指南及新型降脂药物处方的潜在影响
Eur Heart J. 2016 May 1;37(17):1373-9. doi: 10.1093/eurheartj/ehw046. Epub 2016 Feb 24.
10
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.ODYSSEY FH I和FH II：735例杂合子家族性高胆固醇血症患者接受阿利西尤单抗治疗78周的结果
Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1.